De novo implantation vs. upgrade cardiac resynchronization therapy

a systematic review and meta-analysis

Annamaria Kosztin, Mate Vamos, Daniel Aradi, Walter Richard Schwertner, Attila Kovacs, Klaudia Vivien Nagy, E. Zima, L. Gellér, G. Duray, Valentina Kutyifa, B. Merkely

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Patients with conventional pacemakers or implanted defibrillators are often considered for cardiac resynchronization therapy (CRT). Our aim was to summarize the available evidences regarding the clinical benefits of upgrade procedures. A systematic literature search was performed from studies published between 2006 and 2017 in order to compare the outcome of CRT upgrade vs. de novo implantations. Outcome data on all-cause mortality, heart failure events, New York Heart Association (NYHA) Class, QRS narrowing and echocardiographic parameters were analysed. A total of 16 reports were analysed comprising 489,568 CRT recipients, of whom 468,205 patients underwent de novo and 21,363 upgrade procedures. All-cause mortality was similar after CRT upgrade compared to de novo implantations (RR 1.19, 95% CI 0.88–1.60, p = 0.27). The risk of heart failure was also similar in both groups (RR 0.96, 95% CI 0.70–1.32, p = 0.81). There was no significant difference in clinical response after CRT upgrade compared to de novo implantations in terms of improvement in left ventricular ejection fraction (ΔEF de novo − 6.85% vs. upgrade − 9.35%; p = 0.235), NYHA class (ΔNYHA de novo − 0.74 vs. upgrade − 0.70; p = 0.737) and QRS narrowing (ΔQRS de novo − 9.6 ms vs. upgrade − 29.5 ms; p = 0.485). Our systematic review and meta-analysis of currently available studies reports that CRT upgrade is associated with similar risk for all-cause mortality compared to de novo resynchronization therapy. Benefits on reverse remodelling and functional capacity improved similarly in both groups suggesting that CRT upgrade may be safely and effectively offered in routine practice. Clinical Trial Registration: Prospero Database—CRD42016043747.

Original languageEnglish
Pages (from-to)15-26
Number of pages12
JournalHeart Failure Reviews
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Cardiac Resynchronization Therapy
Meta-Analysis
Mortality
Heart Failure
Defibrillators
Stroke Volume
Clinical Trials

Keywords

  • Cardiac resynchronization therapy
  • CRT upgrade
  • De novo CRT
  • Heart failure
  • Meta-analyses
  • Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

De novo implantation vs. upgrade cardiac resynchronization therapy : a systematic review and meta-analysis. / Kosztin, Annamaria; Vamos, Mate; Aradi, Daniel; Schwertner, Walter Richard; Kovacs, Attila; Nagy, Klaudia Vivien; Zima, E.; Gellér, L.; Duray, G.; Kutyifa, Valentina; Merkely, B.

In: Heart Failure Reviews, Vol. 23, No. 1, 01.01.2018, p. 15-26.

Research output: Contribution to journalReview article

Kosztin, Annamaria ; Vamos, Mate ; Aradi, Daniel ; Schwertner, Walter Richard ; Kovacs, Attila ; Nagy, Klaudia Vivien ; Zima, E. ; Gellér, L. ; Duray, G. ; Kutyifa, Valentina ; Merkely, B. / De novo implantation vs. upgrade cardiac resynchronization therapy : a systematic review and meta-analysis. In: Heart Failure Reviews. 2018 ; Vol. 23, No. 1. pp. 15-26.
@article{9136ceab65364bd8b7e7886c42de2c61,
title = "De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis",
abstract = "Patients with conventional pacemakers or implanted defibrillators are often considered for cardiac resynchronization therapy (CRT). Our aim was to summarize the available evidences regarding the clinical benefits of upgrade procedures. A systematic literature search was performed from studies published between 2006 and 2017 in order to compare the outcome of CRT upgrade vs. de novo implantations. Outcome data on all-cause mortality, heart failure events, New York Heart Association (NYHA) Class, QRS narrowing and echocardiographic parameters were analysed. A total of 16 reports were analysed comprising 489,568 CRT recipients, of whom 468,205 patients underwent de novo and 21,363 upgrade procedures. All-cause mortality was similar after CRT upgrade compared to de novo implantations (RR 1.19, 95{\%} CI 0.88–1.60, p = 0.27). The risk of heart failure was also similar in both groups (RR 0.96, 95{\%} CI 0.70–1.32, p = 0.81). There was no significant difference in clinical response after CRT upgrade compared to de novo implantations in terms of improvement in left ventricular ejection fraction (ΔEF de novo − 6.85{\%} vs. upgrade − 9.35{\%}; p = 0.235), NYHA class (ΔNYHA de novo − 0.74 vs. upgrade − 0.70; p = 0.737) and QRS narrowing (ΔQRS de novo − 9.6 ms vs. upgrade − 29.5 ms; p = 0.485). Our systematic review and meta-analysis of currently available studies reports that CRT upgrade is associated with similar risk for all-cause mortality compared to de novo resynchronization therapy. Benefits on reverse remodelling and functional capacity improved similarly in both groups suggesting that CRT upgrade may be safely and effectively offered in routine practice. Clinical Trial Registration: Prospero Database—CRD42016043747.",
keywords = "Cardiac resynchronization therapy, CRT upgrade, De novo CRT, Heart failure, Meta-analyses, Mortality",
author = "Annamaria Kosztin and Mate Vamos and Daniel Aradi and Schwertner, {Walter Richard} and Attila Kovacs and Nagy, {Klaudia Vivien} and E. Zima and L. Gell{\'e}r and G. Duray and Valentina Kutyifa and B. Merkely",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10741-017-9652-1",
language = "English",
volume = "23",
pages = "15--26",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - De novo implantation vs. upgrade cardiac resynchronization therapy

T2 - a systematic review and meta-analysis

AU - Kosztin, Annamaria

AU - Vamos, Mate

AU - Aradi, Daniel

AU - Schwertner, Walter Richard

AU - Kovacs, Attila

AU - Nagy, Klaudia Vivien

AU - Zima, E.

AU - Gellér, L.

AU - Duray, G.

AU - Kutyifa, Valentina

AU - Merkely, B.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients with conventional pacemakers or implanted defibrillators are often considered for cardiac resynchronization therapy (CRT). Our aim was to summarize the available evidences regarding the clinical benefits of upgrade procedures. A systematic literature search was performed from studies published between 2006 and 2017 in order to compare the outcome of CRT upgrade vs. de novo implantations. Outcome data on all-cause mortality, heart failure events, New York Heart Association (NYHA) Class, QRS narrowing and echocardiographic parameters were analysed. A total of 16 reports were analysed comprising 489,568 CRT recipients, of whom 468,205 patients underwent de novo and 21,363 upgrade procedures. All-cause mortality was similar after CRT upgrade compared to de novo implantations (RR 1.19, 95% CI 0.88–1.60, p = 0.27). The risk of heart failure was also similar in both groups (RR 0.96, 95% CI 0.70–1.32, p = 0.81). There was no significant difference in clinical response after CRT upgrade compared to de novo implantations in terms of improvement in left ventricular ejection fraction (ΔEF de novo − 6.85% vs. upgrade − 9.35%; p = 0.235), NYHA class (ΔNYHA de novo − 0.74 vs. upgrade − 0.70; p = 0.737) and QRS narrowing (ΔQRS de novo − 9.6 ms vs. upgrade − 29.5 ms; p = 0.485). Our systematic review and meta-analysis of currently available studies reports that CRT upgrade is associated with similar risk for all-cause mortality compared to de novo resynchronization therapy. Benefits on reverse remodelling and functional capacity improved similarly in both groups suggesting that CRT upgrade may be safely and effectively offered in routine practice. Clinical Trial Registration: Prospero Database—CRD42016043747.

AB - Patients with conventional pacemakers or implanted defibrillators are often considered for cardiac resynchronization therapy (CRT). Our aim was to summarize the available evidences regarding the clinical benefits of upgrade procedures. A systematic literature search was performed from studies published between 2006 and 2017 in order to compare the outcome of CRT upgrade vs. de novo implantations. Outcome data on all-cause mortality, heart failure events, New York Heart Association (NYHA) Class, QRS narrowing and echocardiographic parameters were analysed. A total of 16 reports were analysed comprising 489,568 CRT recipients, of whom 468,205 patients underwent de novo and 21,363 upgrade procedures. All-cause mortality was similar after CRT upgrade compared to de novo implantations (RR 1.19, 95% CI 0.88–1.60, p = 0.27). The risk of heart failure was also similar in both groups (RR 0.96, 95% CI 0.70–1.32, p = 0.81). There was no significant difference in clinical response after CRT upgrade compared to de novo implantations in terms of improvement in left ventricular ejection fraction (ΔEF de novo − 6.85% vs. upgrade − 9.35%; p = 0.235), NYHA class (ΔNYHA de novo − 0.74 vs. upgrade − 0.70; p = 0.737) and QRS narrowing (ΔQRS de novo − 9.6 ms vs. upgrade − 29.5 ms; p = 0.485). Our systematic review and meta-analysis of currently available studies reports that CRT upgrade is associated with similar risk for all-cause mortality compared to de novo resynchronization therapy. Benefits on reverse remodelling and functional capacity improved similarly in both groups suggesting that CRT upgrade may be safely and effectively offered in routine practice. Clinical Trial Registration: Prospero Database—CRD42016043747.

KW - Cardiac resynchronization therapy

KW - CRT upgrade

KW - De novo CRT

KW - Heart failure

KW - Meta-analyses

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85031746075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031746075&partnerID=8YFLogxK

U2 - 10.1007/s10741-017-9652-1

DO - 10.1007/s10741-017-9652-1

M3 - Review article

VL - 23

SP - 15

EP - 26

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 1

ER -